Form 4: OptiNose Executive Michael F. Marino III Reports Stock and Option Grants

Chief Legal Officer Michael F. Marino III reports the acquisition of restricted stock units and stock options in OptiNose, Inc.

Summary

• Michael F. Marino III, Chief Legal Officer & Corp Sec of OptiNose, Inc., reported transactions involving the company's securities.
• On February 21, 2025, Marino was granted 21,150 restricted stock units (RSUs) and an option to purchase 10,575 shares of common stock.
• The RSUs vest 25% on February 21, 2026, and the remainder vest in equal quarterly installments over the following three years, contingent upon continued service.
• The stock options also vest over a four-year period, with 25% vesting on February 21, 2026, and the rest vesting in equal monthly installments over the remaining three years, also subject to continued service.
• The exercise price for the stock options is $5.77.
• All share numbers reflect a 1-for-15 reverse stock split that OptiNose, Inc. effected on December 30, 2024.
• Following the reported transactions, Marino directly owns 57,429 shares of common stock and 10,575 stock options.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The grant of stock options and RSUs is a standard practice and suggests confidence in the executive's continued contribution to the company. The reverse stock split is a neutral event.

Positives

• The grant of RSUs and stock options to the Chief Legal Officer aligns his interests with those of the shareholders, incentivizing him to contribute to the company's long-term success.

Future Outlook

The vesting schedules for the RSUs and stock options are contingent upon continued service with the Issuer, suggesting an expectation of Marino's continued employment.

Industry Context

Stock option and RSU grants are common compensation practices for executives in publicly traded companies, aligning their interests with shareholders and incentivizing long-term value creation.

Comparison to Industry Standards

• Executive compensation packages, including stock options and RSUs, are standard practice in the pharmaceutical and biotechnology industries.
• Companies like Teva Pharmaceuticals, Mylan (now Viatris), and Amgen also utilize similar equity-based compensation to incentivize their executives.
• The vesting schedules and exercise prices are generally aligned with industry norms to promote long-term commitment and performance.

Stakeholder Impact

• Shareholders may view the equity grants positively as they align management's interests with the company's long-term performance.
• Employees may see this as a positive sign of the company's commitment to its leadership team.

Key Dates